These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 12434581

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM, Centurión D, Valdivia LF, de Vries P, Saxena PR.
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
    Villalón CM, Centurión D, Sánchez-López A, De Vries P, Saxena P.
    Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
    [Abstract] [Full Text] [Related]

  • 5. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM, VanDenBrink AM.
    Mini Rev Med Chem; 2017 Dec; 17(11):928-938. PubMed ID: 27465216
    [Abstract] [Full Text] [Related]

  • 6. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL, Goadsby PJ.
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [Abstract] [Full Text] [Related]

  • 7. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors.
    De Vries P, Villalón CM, Heiligers JP, Saxena PR.
    Br J Pharmacol; 1998 Apr; 123(8):1561-70. PubMed ID: 9605562
    [Abstract] [Full Text] [Related]

  • 8. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML, Schenck K.
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [Abstract] [Full Text] [Related]

  • 9. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A.
    Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
    Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A.
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neurogenic inflammation in the context of migraine.
    Williamson DJ, Hargreaves RJ.
    Microsc Res Tech; 2001 May 01; 53(3):167-78. PubMed ID: 11301492
    [Abstract] [Full Text] [Related]

  • 15. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
    Dahlöf C, Maassen Van Den Brink A.
    Headache; 2012 Apr 01; 52(4):707-14. PubMed ID: 22444161
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.
    Muñoz-Islas E, Lozano-Cuenca J, González-Hernández A, Ramírez-Rosas MB, Sánchez-López A, Centurión D, Maassenvandenbrink A, Villalón CM.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):133-8. PubMed ID: 19460365
    [Abstract] [Full Text] [Related]

  • 18. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
    Peroutka SJ.
    Neurology; 1993 Jun 01; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
    [Abstract] [Full Text] [Related]

  • 19. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
    Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E.
    Mol Pharmacol; 1996 Aug 01; 50(2):219-23. PubMed ID: 8700126
    [Abstract] [Full Text] [Related]

  • 20. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward.
    Tfelt-Hansen PC, Koehler PJ.
    Cephalalgia; 2008 Aug 01; 28(8):877-86. PubMed ID: 18460007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.